Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (33)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  3. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  4. Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 2945-2953

  5. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

2023

  1. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

  2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  3. Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Cancer Medicine, Vol. 12, Núm. 4, pp. 3999-4009

2022

  1. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

    ESMO Open, Vol. 7, Núm. 2

  2. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort

    Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735

  3. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma

    Blood, Vol. 139, Núm. 3, pp. 384-398

2021

  1. Intratumoural administration and tumour tissue targeting of cancer immunotherapies

    Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

2019

  1. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility

    Nature Communications, Vol. 9, Núm. 1

  2. Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

    Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174

2017

  1. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Nature Communications, Vol. 8, Núm. 1

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

    Nature Medicine, Vol. 21, Núm. 6, pp. 555-559

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508